NEW YORK, May 27 The American Stock Exchange(R) (Amex(R))today listed the common stock of Rexahn Pharmaceuticals, Inc. under the tickersymbol RNN.
Rexahn Pharmaceuticals is a biopharmaceutical company leveraging itsproprietary technology platform to discover, develop and commercializeinnovative treatments for cancer, central nervous system disorders, sexualdysfunction and other unmet medical needs. Rexahn's compounds are designed touniquely treat various disease states while significantly minimizing sideeffects in order to allow patients to regain quality of life through therapy.
"We are pleased to welcome Rexahn Pharmaceuticals to the American StockExchange," said Neal Wolkoff, Chairman and CEO, of the Amex. "We look forwardto working with Rexahn in building increased awareness and visibility withinthe investment community."
"As we continue to aggressively pursue our clinical development efforts,our listing on the Amex will increase shareholder value and provide expandedvisibility to the investment community and capital markets, at large," statedDr. Chang H. Ahn, Chairman and Chief Executive Officer of Rexahn.
The specialist for Rexahn Pharmaceuticals, Inc. is AGS SpecialistPartners. For further information on RNN and other Amex-listed companies,please visit www.amex.com.
About American Stock Exchange
The American Stock Exchange(R) (Amex(R)) offers trading across a fullrange of equities, options and exchange traded funds (ETFs), includingstructured products and HOLDRS(SM). In addition to its role as a nationalequities market, the Amex is the pioneer of the ETF, responsible for bringingthe first domestic product to market in 1993. Leading the industry in ETFlistings, the Amex lists 401 ETFs to date. The Amex is also one of the largestoptions exchanges in the U.S., trading options on broad-based and sectorindexes as well as domestic and foreign stocks. For more information, pleasevisit www.amex.com.
SOURCE American Stock Exchange